[NEWSMP] The combined market capitalization of the KOSPI Pharmaceuticals Index's constituent stocks rebounded above KRW 140 trillion, driven by Samsung Biologics and Celltrion.According to the Korea Exchange, the combined market capitalization of the 49 constituent stocks of the KOSPI Pharmaceutical

[NEWSMP] Experts remain optimistic about the business outlook for Korea's biohealth industry, although their expectations have gradually softened.At the same time, concerns persist over declining new investment and widening disparities among companies, raising questions about the industry's future t

[NEWSMP} The business outlook index for Korea's biohealth industry declined somewhat in the fourth quarter after rising sharply in the third quarter.Nevertheless, positive assessments continued to prevail in exports, facilities investment, the operation ratio of facilities, and employment.On the 18t

[NEWSMP] Korean pharmaceutical and biotech stocks generally struggled to gain momentum in the third quarter. Among the constituents of the pharmaceutical indices on the two markets, four KOSPI-listed stocks and two KOSDAQ-listed stocks ranked among the top 100 in terms of share price gains. (All fig

[NEWSMP] The business outlook for the Korean pharmaceutical manufacturing industry, which had shown some improvement in the second half of the year, is becoming increasingly negative.According to the “Business Survey and Economic Sentiment Index for September 2026” report released by the Bank of Kor

[NEWSMP] A survey of industry experts conducted by the Korea Institute for Industrial Economics and Trade (KIET) showed that sentiment toward the bio-health industry remained positive.The September Professional Survey Index (PSI) for business conditions came in at 100, well below the previous month’

[NEWSMP] Exports of pharmaceutical products (HS 30) have continued to rise sharply this year, following strong growth last year. However, imports have grown at an even faster pace, pushing the cumulative trade deficit above $1 billion in just eight months.According to the Korea Customs Service, expo

[NEWSMP] The combined market capitalization of the KOSPI Pharmaceutical Index constituents increased in August, buoyed by news of Hanmi Pharmaceutical’s technology licensing deal.According to the Korea Exchange, the combined market capitalization of the 49 constituents of the KOSPI Pharmaceutical In

[NEWSMP] The business outlook for the biohealth industry, previously dominated by negative sentiment, has reversed sharply and turned overwhelmingly positive.According to the “Expert Survey on Industrial Business Conditions: August 2026 Conditions and September Outlook” released by the Korea Institu

[NEWSMP] A total of 24 listed pharmaceutical and biotech companies with fiscal years ending in December posted sales of more than KRW 100 billion in the second quarter, based on separate financial statements.Samsung Biologics topped the list. After posting sales of KRW 1.0142 trillion in the second

[NEWSMP] According to Newsmp’s analysis of semiannual reports of listed pharmaceutical companies with fiscal years ending in November or December, sales at the 66 companies surveyed grew by an average of 9.0% in the second quarter, approaching double-digit growth. All figures are based on separate f

[NEWSMP] The combined revenue of South Korea’s five leading pharmaceutical companies increased 9.7% in the second quarter, while their operating profit surged 34.4%, pushing their combined operating margin into double digits. (based on separate financial statements)Hanmi Pharm, in particular, posted

The weakness in pharmaceutical stocks persisted in July, as 30 of the 49 constituents of the KOSPI Pharmaceutical Index posted share price declines.Nevertheless, the KOSPI Pharmaceutical Index's total market capitalization rebounded above the KRW 140 trillion mark (excluding preferred shares), as th

[NEWSMP] Industry experts have turned increasingly optimistic about the outlook for the biohealth sector.Unlike the first quarter, when negative assessments increased sharply, sentiment turned more positive in the second quarter.According to the Manufacturing Business Survey for Second Quarter 2026

South Korea's pharmaceutical product exports exceeded USD 1.1 billion for the first time ever in June, driving first-half exports above USD 5 billion and setting a new all-time record.However, imports of pharmaceutical products also increased sharply, resulting in the trade balance swinging into def

[NEWSMP] Pharmaceutical stocks struggled throughout the first half of the year.Among the 49 constituents of the KOSPI Pharmaceutical Index (excluding preferred shares), only four posted gains during the first half of the year, while 44 recorded declines (based on adjusted share prices).According to

[NEWSMP] First-Half Biohealth Industry Exports Exceed $9 BillionAfter surpassing the $10 billion mark for the first time on record last year, Korea's pharmaceutical exports have continued to grow rapidly this year and are now on track to exceed the $12 billion mark.According to the Ministry of Trade

[NEWSMP] The Bank of Korea delivered a more pessimistic outlook for Korea's pharmaceutical manufacturing industry. However, expectations for exports have strengthened.According to the June 2026 Business Survey and Economic Sentiment Index released by the Bank of Korea on June 25, both the June busin

[NEWSMP] After presenting a markedly improved outlook for the biohealth industry last month, the Korea Institute for Industrial Economics & Trade (KIET) has once again revised its forecast downward.On June 21, KIET released the Industrial Expert Survey Results: June 2026 Conditions and July 2026 Out

[NEWSMP] While pharmaceutical product exports continue to grow strongly, the trade deficit has widened further.According to the Korea Customs Service, exports of pharmaceutical products (HS30) totaled $834.31 million in May, up 8.8% from a year earlier, extending their growth streak to seven consecu